MX2022005465A - Metodos de tratamiento con modulador de miosina. - Google Patents
Metodos de tratamiento con modulador de miosina.Info
- Publication number
- MX2022005465A MX2022005465A MX2022005465A MX2022005465A MX2022005465A MX 2022005465 A MX2022005465 A MX 2022005465A MX 2022005465 A MX2022005465 A MX 2022005465A MX 2022005465 A MX2022005465 A MX 2022005465A MX 2022005465 A MX2022005465 A MX 2022005465A
- Authority
- MX
- Mexico
- Prior art keywords
- myosin
- treatment
- methods
- mavacamten
- modulator
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933517P | 2019-11-10 | 2019-11-10 | |
| US201962933970P | 2019-11-11 | 2019-11-11 | |
| US201962935922P | 2019-11-15 | 2019-11-15 | |
| US202063001473P | 2020-03-29 | 2020-03-29 | |
| US202063002302P | 2020-03-30 | 2020-03-30 | |
| US202063006701P | 2020-04-07 | 2020-04-07 | |
| US202063022573P | 2020-05-10 | 2020-05-10 | |
| US202063059143P | 2020-07-30 | 2020-07-30 | |
| US202063064450P | 2020-08-12 | 2020-08-12 | |
| PCT/US2020/059893 WO2021092598A1 (en) | 2019-11-10 | 2020-11-10 | Methods of treatment with myosin modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005465A true MX2022005465A (es) | 2022-08-08 |
Family
ID=75849342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005465A MX2022005465A (es) | 2019-11-10 | 2020-11-10 | Metodos de tratamiento con modulador de miosina. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230158027A1 (https=) |
| EP (1) | EP4054588A4 (https=) |
| JP (1) | JP7830321B2 (https=) |
| KR (1) | KR20220113387A (https=) |
| CN (1) | CN114945372A (https=) |
| AU (1) | AU2020378197A1 (https=) |
| BR (1) | BR112022008641A2 (https=) |
| CA (1) | CA3157629A1 (https=) |
| CL (1) | CL2022001217A1 (https=) |
| IL (1) | IL292840A (https=) |
| MX (1) | MX2022005465A (https=) |
| TW (1) | TW202134259A (https=) |
| WO (1) | WO2021092598A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3645002T3 (da) | 2017-06-30 | 2024-12-16 | Amgen Inc | Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| HUE069154T2 (hu) * | 2020-01-28 | 2025-02-28 | Assia Chem Ind Ltd | A mavakamten szilárd állapotú formái és eljárás elõállításukra |
| MX2023002024A (es) * | 2020-08-28 | 2023-05-10 | Myokardia Inc | Métodos de tratamiento con modulador de miosina. |
| DK4243825T3 (da) | 2020-11-12 | 2025-12-01 | Amgen Inc | Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper |
| CN115461052B (zh) * | 2020-11-25 | 2023-12-22 | 深圳信立泰药业股份有限公司 | Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途 |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| CN112939876A (zh) * | 2021-03-10 | 2021-06-11 | 杭州科巢生物科技有限公司 | Mavacamten的晶型I及其制备方法 |
| WO2022189599A1 (en) * | 2021-03-12 | 2022-09-15 | Sandoz Ag | Crystalline forms of mavacamten for the treatment of hcm |
| PT4370116T (pt) * | 2021-07-16 | 2025-03-14 | Cytokinetics Inc | Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva |
| WO2023102452A1 (en) * | 2021-12-02 | 2023-06-08 | Tenax Therapeutics, Inc. | Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure |
| CN116410143A (zh) * | 2021-12-29 | 2023-07-11 | 杭州奥默医药股份有限公司 | 一种多取代脲嘧啶衍生物及其制备方法和应用 |
| CA3248508A1 (en) | 2022-04-13 | 2023-10-19 | Assia Chemical Industries Ltd. | SOLID STATE FORMS OF MAVACAMTEN AND THEIR PREPARATION METHOD |
| EP4514355A1 (en) * | 2022-04-26 | 2025-03-05 | MyoKardia, Inc. | Methods of administering myosin inhibitors |
| JP2025534288A (ja) | 2022-09-26 | 2025-10-15 | エッジワイズ セラピューティクス， インコーポレイテッド | １，４－ジヒドロキナゾリノン化合物およびその使用 |
| WO2024097284A1 (en) * | 2022-11-02 | 2024-05-10 | MyoKardia, Inc. | Mavacamten and derivatives thereof for use in treating atrial dysfunction |
| EP4688756A1 (en) | 2023-03-27 | 2026-02-11 | Edgewise Therapeutics, Inc. | Quinazoline dione compounds and uses thereof |
| WO2024206339A1 (en) | 2023-03-27 | 2024-10-03 | Edgewise Therapeutics, Inc. | Quinolinone amide compounds and uses thereof |
| IT202300016653A1 (it) | 2023-08-03 | 2025-02-03 | Olon Spa | Processo per preparare mavacamten e intermedio di processo. |
| WO2025046606A1 (en) | 2023-08-26 | 2025-03-06 | Micro Labs Limited | Granules of mavacamten for oral administration |
| WO2025096779A2 (en) * | 2023-11-01 | 2025-05-08 | Bristol Myers Squibb Company | Methods of treatment with a myosin inhibitor using protein levels |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0908193D0 (en) * | 2009-05-13 | 2009-06-24 | Albright Patents | Treatment of disease state |
| SMT202000071T1 (it) * | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| EP3399907A4 (en) * | 2016-01-04 | 2019-08-28 | Aventusoft, LLC | SYSTEM AND METHOD FOR MEASURING HEMODYNAMIC PARAMETERS FROM THE HEADLAPPING SIGNALS |
| CA3071948A1 (en) * | 2017-08-04 | 2019-02-07 | MyoKardia, Inc. | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
-
2020
- 2020-11-10 EP EP20884325.0A patent/EP4054588A4/en active Pending
- 2020-11-10 MX MX2022005465A patent/MX2022005465A/es unknown
- 2020-11-10 TW TW109139230A patent/TW202134259A/zh unknown
- 2020-11-10 AU AU2020378197A patent/AU2020378197A1/en active Pending
- 2020-11-10 CA CA3157629A patent/CA3157629A1/en active Pending
- 2020-11-10 JP JP2022526496A patent/JP7830321B2/ja active Active
- 2020-11-10 CN CN202080092267.1A patent/CN114945372A/zh active Pending
- 2020-11-10 KR KR1020227019428A patent/KR20220113387A/ko active Pending
- 2020-11-10 WO PCT/US2020/059893 patent/WO2021092598A1/en not_active Ceased
- 2020-11-10 BR BR112022008641A patent/BR112022008641A2/pt unknown
- 2020-11-10 US US17/775,375 patent/US20230158027A1/en active Pending
-
2022
- 2022-05-08 IL IL292840A patent/IL292840A/en unknown
- 2022-05-10 CL CL2022001217A patent/CL2022001217A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4054588A1 (en) | 2022-09-14 |
| CA3157629A1 (en) | 2021-05-14 |
| BR112022008641A2 (pt) | 2022-09-13 |
| TW202134259A (zh) | 2021-09-16 |
| AU2020378197A1 (en) | 2022-05-26 |
| KR20220113387A (ko) | 2022-08-12 |
| CL2022001217A1 (es) | 2023-01-13 |
| WO2021092598A1 (en) | 2021-05-14 |
| US20230158027A1 (en) | 2023-05-25 |
| JP2023501453A (ja) | 2023-01-18 |
| CN114945372A (zh) | 2022-08-26 |
| IL292840A (en) | 2022-07-01 |
| JP7830321B2 (ja) | 2026-03-16 |
| EP4054588A4 (en) | 2023-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005465A (es) | Metodos de tratamiento con modulador de miosina. | |
| MX2023002024A (es) | Métodos de tratamiento con modulador de miosina. | |
| EP4585262A3 (en) | Methods of treating mitochondrial dysfunction | |
| HK1214765A1 (zh) | 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途 | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| FI3840753T3 (fi) | Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio | |
| JP2015519329A5 (https=) | ||
| WO2007149283A3 (en) | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload | |
| AR103118A1 (es) | Tratamientos médicos basados en anamorelina | |
| AU2018326364A1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| MX2021009384A (es) | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. | |
| MX379191B (es) | Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| Kumar et al. | An observational study to compare the outcome of local steroid injections and ultrasonic wave therapy in frozen shoulder patients | |
| EP4523750A3 (en) | Methods of reducing cerebrovascular events in patients with fabry disease | |
| Rodda et al. | Quality of life outcomes: ASCENDE-RT a multicenter randomized trial of radiation therapy for prostate cancer | |
| MX2021014093A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| CL2022001426A1 (es) | Formulación pediátrica de liberación inmediata del abridor de canales de potasio ezogabina | |
| AU2020360413A8 (en) | Methods of treating conditions related to the S1P1 receptor | |
| BR112015023697A2 (pt) | inibidores de ácidos biliares de reciclagem para tratamento de esôfago de barrett e doença do refluxo gastroesofágico | |
| WO2014023869A3 (es) | Aplicacion terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana | |
| WO2022139753A3 (en) | Use of benidipine for the treatment of epilepsy disease |